GB Sciences, Inc. (GBLX)
Stock Price:
$0.0291 USD
0.0010 (3.56%)
Updated November 27, 12:48 PM EST - Market closed
Key Info
| Market Cap |
7.78M |
| Revenue (ttm) |
1.59M |
| Net Income (ttm) |
-9.94M |
| Shares Out |
267.43M |
| EPS (ttm) |
-0.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$0.0291 |
| Previous Close |
$0.0281 |
| Change ($) |
0.0010 |
| Change (%) |
3.56% |
| Day's Open |
0.0286 |
| Day's Range |
0.0278 - 0.0295 |
| Day's Volume |
118,458 |
| 52-Week Range |
0.02 - 0.065 |
More Stats
| Market Cap |
7.78M |
| Enterprise Value |
10.03M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
267.43M |
| Float |
n/a |
| EPS (basic) |
-0.04 |
| EPS (diluted) |
-0.04 |
| FCF / Share |
0.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.18 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.90 |
| PB Ratio |
1.08 |
| Revenue |
1.59M |
| Operating Income |
-9.38M |
| Net Income |
-9.94M |
| Free Cash Flow |
-1.13M |
| Net Cash |
-2.24M |
| Net Cash / Share |
-0.01 |
| Gross Margin |
-28.25% |
| Operating Margin |
-590.09% |
| Profit Margin |
-625.10% |
| FCF Margin |
-71.10% |
| ROA |
-14.99% |
| ROE |
-173.62% |
| ROIC |
-71.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 3.12 | 3.45 | 2.51 | - | - | - | - | - |
| Revenue Growth | -9.67% | 37.61% | - | - | - | - | - | - |
| Gross Profit | -0.88 | 0.21 | 1.73 | - | - | - | - | - |
| Operating Income | -12.01 | -13.19 | -17.82 | -8.93 | -6.96 | -7.97 | -0.19 | -0.11 |
| Net Income | -12.37 | -23.65 | -22.97 | -9.91 | -6.77 | -7.72 | -0.66 | 0.04 |
| Shares Outstanding | 258 | 210 | 133 | 79.00 | 44.91 | 29.52 | 0.94 | 0.97 |
| Earnings Per Share | -0.05 | -0.11 | -0.17 | -0.13 | -0.15 | -0.26 | -0.70 | 0.04 |
| Operating Cash Flow | -4.48 | -9.86 | -12.25 | -4.47 | -3.56 | -3.50 | -0.36 | -0.04 |
| Capital Expenditures | -0.19 | -1.51 | -3.43 | -3.05 | -0.88 | -0.94 | -0.02 | - |
| Free Cash Flow | -4.67 | -11.37 | -15.68 | -7.52 | -4.45 | -4.44 | -0.38 | -0.04 |
| Cash & Equivalents | 5.38 | 0.18 | 3.58 | 2.69 | 0.03 | - | 0.34 | 0.34 |
| Total Debt | 10.00 | 6.12 | 7.55 | 3.93 | 2.61 | 0.18 | 1.27 | 1.27 |
| Net Cash / Debt | -4.63 | -5.94 | -3.97 | -1.24 | -2.58 | -0.18 | -0.93 | -0.93 |
| Assets | 14.35 | 30.02 | 24.05 | 13.01 | 2.44 | 1.45 | 0.54 | 0.54 |
| Liabilities | 14.44 | 12.87 | 8.42 | 4.60 | 4.41 | 3.38 | 1.55 | 1.55 |
| Book Value | -0.09 | 8.30 | 12.75 | 8.33 | -1.90 | -1.68 | -1.01 | -1.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
GB Sciences, Inc. |
| Country |
United States |
| Employees |
23 |
| CEO |
John Claybron Poss |
Stock Information
| Ticker Symbol |
GBLX |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: GBLX |
Description
GB Sciences engages in the research and development of cannabinoid medicines in North America and Europe. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.